Asset Details
Do you wish to reserve the book?
CD 44v, S 1 PR 1, HER 3, MET and cancer‐associated amino acid transporters are promising targets for the pancreatic cancers characterized using m A b
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
CD 44v, S 1 PR 1, HER 3, MET and cancer‐associated amino acid transporters are promising targets for the pancreatic cancers characterized using m A b
Do you wish to request the book?
CD 44v, S 1 PR 1, HER 3, MET and cancer‐associated amino acid transporters are promising targets for the pancreatic cancers characterized using m A b
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
CD 44v, S 1 PR 1, HER 3, MET and cancer‐associated amino acid transporters are promising targets for the pancreatic cancers characterized using m A b
2025
Overview
Effective therapies have yet to be established for pancreatic ductal adenocarcinomas (PDAC) even though it is the most aggressive cancer. In the present study, PDAC was analyzed using novel rat mAbs against membrane proteins in conjunction with flow cytometry and immunohistochemistry. Human epidermal growth receptor (HER)1–4, mesenchymal to epithelial transition factor (MET), sphingosine‐1‐phospahate receptor 1 (S1PR1), l ‐type amino acid transporter 1 (LAT1), system x − c transporter (xCT), alanine‐serine‐cysteine transporter (ASCT2), cationic amino acid transporter 1 (CAT1) and variant CD44 (CD44v) were expressed at high frequencies in both in vitro and in vivo PDAC. Internalization of membrane proteins by mAbs and growth inhibition by toxin‐linked mAbs were demonstrated in many PDAC cell lines, and mAbs against S1PR1, ASCT2, HER3 and CD44v inhibited the growth of xenografted MIA PaCa‐2 PDAC cells. Furthermore, CD44v‐high PDAC showed high mRNA expression of HER1–3, MET and CD44v, and was correlated with poor prognosis. Taken together, our results suggest that CD44v, S1PR1, HER3, MET and the above‐mentioned cancer‐associated amino acid transporters might be promising targets for the diagnosis and treatment of PDAC.
We currently cannot retrieve any items related to this title. Kindly check back at a later time.